Janney Montgomery Scott
CORT icon

Janney Montgomery Scott’s Corcept Therapeutics CORT Stock Holding History

Janney Montgomery Scott’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24,932
Closed -$810K – 2689
2024
Q2 		$810K Sell
24,932
-3,078
-11% -$84.3K ﹤0.01% 1571
2024
Q1 		$706K Buy
+28,010
New +$662K ﹤0.01% 1725

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Janney Montgomery Scott's CORT Position: Q3 2024 in Review

Janney Montgomery Scott sold out of Corcept Therapeutics (CORT) in Q3 2024, closing a stake of 24,932 shares — an estimated $810K sold.

Janney Montgomery Scott first reported a position in CORT in Q1 2024 and held it in 2 quarters. The position peaked at $810K in Q2 2024. 321 funds tracked by Wall St. Rank hold CORT as of Q3 2024.

  • Janney Montgomery Scott reported no remaining Corcept Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Janney Montgomery Scott sold 24,932 Corcept Therapeutics shares in Q3 2024, an estimated $810K.
  • Janney Montgomery Scott first reported a position in Corcept Therapeutics in Q1 2024 and held it in 2 quarters.
  • Janney Montgomery Scott's Corcept Therapeutics position peaked at $810K in Q2 2024.
  • 321 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2024.

Based on Janney Montgomery Scott's 13F filing for Q3 2024, filed 29 Oct 2024.